La Merie

March 2008

• March 28, 2008: Cancer and TNF antibodies boost Biologics Sales in 2007

February 2008

• Frebryary 11, 2008: 2008 is a decisive year for the validation of the asthma target interleukin-13

July 2007

• July 23, 2007: 114 Blockbuster Drugs Accounted for 2006 Sales of US$ 233.7 bln

May 2007

• May 30, 2007: The imminent change of the antithrombotics market
• May 2, 2007: Up and down with cholesterol management

April 2007

• April 25, 2007: Beyond biogenerics: the real threats for therapeutic proteins

March 2007

• March 15, 2007: La Merie and PharmaPlus team up to provide No-Frills business intelligence solutions
• March 8, 2007: Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success
• March 1, 2007: The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers

February 2007

• February 26, 2007: TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
• February 14, 2007: The market of recombinant coagulation factors is growing with next generation products
• February 5, 2007: Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes
• February 2, 2007: Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26

January 2007

• January 11, 2007: The right balance drives the field of PPAR agonist R&D

[ top of the page ]

September 2006

• September 19, 2006: Delivery improvements of the AMD-drug Lucentis on the way
• September 7, 2006: Biologics define new standard of therapy in psoriasis

August 2006

• August 16, 2006: The Crowded Field of VEGF and VEGF-R Targeting Drugs
• August 1, 2006: A Full Pipeline of Follow-on TNF-Antagonists

June 2006

• June 19, 2006: Biogenerics and new technologies compete with 1st generation major protein products
• June 2, 2006: Imminent launches of new EPO products and consolidation of the biogenerics field

May 2006

• May 30, 2006: Localized delivery of PDE-4 inhibitors to open the therapeutic window
• May 18, 2006: The next generation of interferons needs improvement in efficacy and safety
• May 9, 2006: RNA interference (RNAi) is coming of age as a therapeutic modality

[ top of the page ]

April 2006

• April 24, 2006: Competition is needed in the follicle stimulating hormone (FSH) market
• April 24, 2006: A biogeneric company leads the field of next generation human growth hormone (hGH)

March 2006

• March 13, 2006: The irresistible siren's chant of needle-free insulins
• March 6, 2006: Antibodies are the first wave of IGF-1R antagonists for cancer therapy

February 2006

• February 21, 2006: Dawn has broken for obesity treatment with cannabinoid receptor (CB1) antagonists
• February 13, 2006: TOP 20 Biologics now with sales of US$ 37.7 bln in 2005
• February 6, 2006: Dosing convenience mandates the pipeline of glucagon-like peptide-1 (GLP-1) analogs for type 2 diabetes

January 2006

• January 30, 2006: Emerging diabetes drugs in early development
• January 23, 2006: High interest in inhibitors of the novel target sodium-dependent glucose (co-) transporter (SGLT) for therapy of type 2 diabetes
• January 17, 2006: Tight race to be the first in a new class of dipeptidyl peptidase IV (DPP-IV) inhibitors for the oral treatment of type 2 diabetes

October 2005

• October 31, 2005: Thrombolytic therapy needs innovation
• October 17, 2005: Too many companies with biogeneric G-CSF products compete for a small market
• October 10, 2005: Smaller is better for thrombopoiesis-stimulating agents
• October 6, 2005: Patent expiry of epoetin alfa in Europe attracts 10 companies with biogeneric erythropoietin

[ top of the page ]